Guardant Health (NASDAQ: GH) reported Q1 EPS of ($0.49), $0.40 better than the analyst estimate of ($0.89). Revenue for the quarter came in at $78.7 million versus the consensus estimate of $73.75 million.

“I am proud of our team for their continued hard work this quarter. Despite continuing impacts of COVID, we achieved record revenue and solid growth in our clinical business, and continued to progress our product pipeline,” said Helmy Eltoukhy, PhD, co-founder and CEO. “I am so excited about what is ahead for Guardant and believe 2021 will be a pivotal year for us as we expand our product portfolio and invest across our business to build the foundations for complete cancer testing across the continuum of care.”

GUIDANCE:

Guardant Health sees Q2 2021 revenue of $360-370 million.

For earnings history and earnings-related data on Guardant Health (GH) click here.